TransCode Therapeutics, Inc. (RNAZ)

NASDAQ: RNAZ · Real-Time Price · USD
7.67
+0.28 (3.79%)
Jun 5, 2025, 9:59 AM - Market open
3.79%
Market Cap 6.39M
Revenue (ttm) n/a
Net Income (ttm) -25.51M
Shares Out 833.62K
EPS (ttm) -469.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,255
Open 7.23
Previous Close 7.39
Day's Range 7.23 - 8.18
52-Week Range 6.15 - 1,541.79
Beta 1.33
Analysts Strong Buy
Price Target 280.00 (+3,550.59%)
Earnings Date Jun 17, 2025

About RNAZ

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA-... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 9, 2021
Employees 7
Stock Exchange NASDAQ
Ticker Symbol RNAZ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for RNAZ stock is "Strong Buy" and the 12-month stock price forecast is $280.0.

Price Target
$280.0
(3,550.59% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercia...

8 days ago - PRNewsWire

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

15 patients treated across four escalating dose levels of TTX-MC138 No significant safety or dose limiting toxicities reported 10 patients remain on study with no evidence of disease progression PD an...

4 weeks ago - PRNewsWire

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

BOSTON , May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA thera...

4 weeks ago - PRNewsWire

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON , May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA...

4 weeks ago - PRNewsWire

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

A total of 13 patients treated with four escalating doses of TTX-MC138 No significant safety or dose limiting toxicities reported Two patients have so far maintained stable disease on treatment for at...

5 weeks ago - PRNewsWire

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

BOSTON , April 21, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA th...

6 weeks ago - PRNewsWire

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded en...

2 months ago - PRNewsWire

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

BOSTON , March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA th...

2 months ago - PRNewsWire

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BOSTON , March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that...

2 months ago - PRNewsWire

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3 No significant safety or dose limiting toxicities r...

3 months ago - PRNewsWire

TransCode Therapeutics, Inc. Announces Results of Special Meeting

BOSTON , Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA the...

3 months ago - PRNewsWire

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON , Feb. 6, 2025 /PRNewswire/ -- TransCode Therapeuti...

4 months ago - PRNewsWire

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2 No significant safety or dose limiting toxicities reported in Cohorts 1 and 2 PK data from Cohorts ...

5 months ago - PRNewsWire

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode shares to remain listed on Nasdaq BOSTON , Jan. 7, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer us...

5 months ago - PRNewsWire

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 No significant safety or dose limiting toxicities reported in Cohort 2 New patients...

6 months ago - PRNewsWire

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...

6 months ago - GlobeNewsWire

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced t...

6 months ago - GlobeNewsWire

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced th...

7 months ago - GlobeNewsWire

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleot...

9 months ago - GlobeNewsWire

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced t...

9 months ago - GlobeNewsWire

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to

11 months ago - GlobeNewsWire

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

11 months ago - GlobeNewsWire

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

11 months ago - GlobeNewsWire

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new...

1 year ago - GlobeNewsWire

TransCode Therapeutics Open Letter to Shareholders

BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholder, As y...

1 year ago - GlobeNewsWire